Eli Lilly prices $9bn eight-tranche bond, biggest-ever sale to fund $13bn M&A push

Eli Lilly priced $9bn of investment-grade bonds across eight tranches on Wednesday, the drugmaker’s largest-ever debt sale and the biggest M&A-driven trade in the US dollar high-grade market this year.

The deal funds two recent acquisitions, Centessa Pharmaceuticals at roughly $6.3bn in equity and Kelonia Therapeutics at $3.25bn in upfront cash, with milestone payments that could lift Kelonia’s total consideration to $7bn. Maturities ranged from two years to 40 years. Citigroup, Deutsche Bank, Goldman Sachs and Morgan Stanley led the books.

Investor demand let Lilly tighten pricing aggressively from initial price talk. The 2066 long bond, the 40-year tranche, priced at 80 basis points over Treasuries against IPT around 113 basis points, a 33 basis-point compression that is unusually deep for a single book-build. S&P Global Ratings upgraded Lilly the prior week, lowering the headline risk premium for accounts that buy on rating bands.

A Lilly spokesperson said the company was “encouraged about the interest from investors” in the offering.

Some of the new notes carry a special mandatory redemption provision tied to the Centessa close. If the deal fails to complete, Lilly must repurchase those tranches at 101 cents on the dollar. That is the standard make-whole used when bond proceeds are earmarked for a specific acquisition. The structure strips out the deal-risk discount investors would otherwise demand. It also helped the order book hold up through pricing.

What the tranches funded

The Centessa transaction, announced last month, gives Lilly the orexin receptor 2 agonist cleminorexton, formerly ORX750, plus the broader OX2R pipeline. The drug targets narcolepsy type 2 and idiopathic hypersomnia. Lilly will pay $38.00 per Centessa share in cash. There is also a contingent value right worth up to $9.00 per share, linked to FDA approval milestones. The board expects close in the third quarter of 2026, subject to shareholder approval and a UK High Court sanction.

Carole Ho, president of Lilly Neuroscience, called orexin receptor biology “one of the most compelling mechanistic opportunities” in the field. Centessa chief executive Mario Alberto Accardi said the combination would let the platform reach more patients than a standalone launch.

The Kelonia deal was struck three weeks ago. It brings KLN-1010, an in-vivo CAR-T candidate for multiple myeloma. Conventional CAR-T therapies remove a patient’s T cells, edit them in a lab, and infuse them back. KLN-1010 instead modifies the T cells inside the body. That removes the apheresis step. The step has long constrained CAR-T pricing and patient access.

Lilly will pay $3.25bn upfront. The balance is contingent on clinical, regulatory and commercial milestones. Close is expected in the second half of 2026.

Jacob Van Naarden, Lilly executive vice president and Oncology president, said the early KLN-1010 data was “highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform.” Kelonia chief executive Kevin Friedman said the deal would “broaden the reach of cell therapy beyond the current CAR-T landscape.”

How the market read it

The trade landed into a window of unusually tight high-grade spreads. Average IG option-adjusted spreads were inside their late-February levels. Renewed optimism around US-Iran ceasefire diplomacy helped. So did a 1.6 per cent rally in the S&P 500 to a fresh record on Tuesday. Lilly was one of three IG issuers in the dollar market on Wednesday. The other two also priced tighter from IPT than recent comparables.

The 33 basis-point move on the 40-year was the standout. Long-duration paper from single-A rated pharma issuers had been clearing closer to 90-95 basis points over the curve through April. Bankers on the trade said the order book at peak was multiple times the deal size. They declined to put a specific number on it. The two-year and three-year tranches saw the heaviest reverse-inquiry, accounts said. Most of the front-end demand came from money-market funds parking cash ahead of June.

Strategists read the trade as a marker for the wider new-issue calendar. Spreads at these levels can absorb large M&A prints without the usual concession. That backdrop has been absent for most of the past 18 months. The insider-trading sweep that hit three New York law firms this week did little to chill the deals pipeline.

For the broader IG calendar, the trade signals deal-financing supply can clear at marginal new-issue concessions, even with $9bn in size and an unrated near-term M&A obligation attached. That is a shift from the late-2025 backdrop, when M&A bonds typically priced 15-25 basis points wide of seasoned curves.

What’s next

Lilly now has the cash on hand. Centessa is set to close in the third quarter and Kelonia in the second half. The 101-cents redemption clause on the Centessa-tied tranches keeps a small contingent claim on the balance sheet through close. Absent a regulatory shock, dealers expect those notes to trade in line with the rest of the curve once the UK High Court sanction lands.

The company is also expected to remain active. Lilly has spent more than $13bn on Massachusetts biotech M&A in 2026 alone. That includes the $2.4bn purchase of Watertown-based Orna Therapeutics earlier this year. Chief executive David Ricks has signaled further deals as the GLP-1 cash flow keeps compounding. Wednesday’s clearing levels mean the next leg of that spending can be funded at a low single-A rate inside the long end.